

2 February 2016 EMA/HMPC/39453/2015 Committee on Herbal Medicinal Products (HMPC)

# European Union herbal monograph on Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba Final

Discussion in Working Party on European Union monographs and list (MLWP)	September 2014 January 2015
	March 2015
	May 2015
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	07 July 2015
End of consultation (deadline for comments <sup>1</sup> )	31 October 2015
Rediscussion in MLWP	November 2015
Adoption by HMPC	2 February 2016

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs;
	traditional use; Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.)
	Hayek; Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba; Sideritis
	herba; ironwort

<sup>&</sup>lt;sup>1</sup> No comments were received during the period of public consultation. Therefore the final monograph is published together with the final assessment report and list of references, without an 'Overview of comments received during the public consultation'.



BG (bulgarski): Мурсалски чай, стрък

CS (čeština): nať hojníku DA (dansk): Kortkroneurt DE (Deutsch): Berufskraut

EL (elliniká): Πόα σιδηρίτου EN (English): ironwort

ES (español): Siderita, partes aéreas de

ET (eesti keel): haavarohuürt FI (suomi): raudakki, verso

FR (français): Crapaudine (parties aériennes de)

HR (hrvatski): očistova zelen

HU (magyar): sármányvirág virágos hajtása IT (italiano): Stregonia parti aeree fiorite LT (lietuvių kalba): Timsrų žolė LV (latviešu valoda): Siderītu laksts

MT (Malti): ħaxixa tas-Sideritis

NL (Nederlands): (Griekse) bergthee, kruid

PL (polski): Ziele gojnika

PT (português): Siderite, partes aéreas

RO (română): iarba de ceaiul muntelui cretan

SK (slovenčina): Vňať ránhoja SL (slovenščina): zel sklepnjaka

SV (svenska): Sårmynta, ört

IS (íslenska):

NO (norsk): Gresk fjellte

# European Union herbal monograph on *Sideritis scardica* Griseb.; *Sideritis clandestina* (Bory & Chaub.) Hayek; *Sideritis raeseri* Boiss. & Heldr.; *Sideritis syriaca* L., herba

### 1. Name of the medicinal product

To be specified for the individual finished product.

## 2. Qualitative and quantitative composition<sup>2,3</sup>

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Sideritis scardica Griseb.; Sideritis clandestina (Bory & Chaub.) Hayek, Sideritis raeseri Boiss. & Heldr.; Sideritis syriaca L., herba (ironwort)
	i) Herbal substance
	Not applicable
	ii) Herbal preparations
	Comminuted herbal substance

### 3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

# 4. Clinical particulars

### 4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product used for the

<sup>&</sup>lt;sup>2</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>&</sup>lt;sup>3</sup> Detailed specifications for the herbal substance shall be given by references to bibliographic sources in absence of a monograph in the European Pharmacopoeia, a national pharmacopoeia or national codex currently used officially in a Member State

Well-established use	Traditional use
	relief of cough associated with cold.
	Indication 2)  Traditional herbal medicinal product used for the relief of mild gastrointestinal discomfort.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

# 4.2. Posology and method of administration<sup>4</sup>

Well-established use	Traditional use
	Posology
	Adults and elderly
	Indication 1) and 2)
	Single dose:
	Herbal tea: 2-4 g of the comminuted herbal substance in 150-200 ml of water as a herbal infusion 2-3 times daily
	Daily dose up to 12 g
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Indication 1)
	If the symptoms persist longer than 1 week, during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indication 2)
	If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use

 $<sup>^4</sup>$  For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

### 4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance and to other plants of the Lamiaceae (Labiatae) family.

### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children and adolescents under 18 years of age has not been established due to lack of adequate data.  If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

# 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported

### 4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
	No fertility data available.

### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

### 4.8. Undesirable effects

Well-established use	Traditional use
	None known
	If adverse reactions occur, a doctor or a qualified

Well-established use	Traditional use
	health care practitioner should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

## 5. Pharmacological properties

### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

### 5.3. Preclinical safety data

Directive necessar  Four Sid polarity n-heptar typhimus 1537 and activatio mutager  Tests on	uired as per Article 16c(1)(a)(iii) of e 2001/83/EC as amended, unless ry for the safe use of the product.  Ideritis scardica dry extracts of different (water, 20% and 50% V/V ethanol, and ne) were tested (AMES-test in Salmonella virium strains TA 98, TA 100, TA 1535, TA d TA 102 with and without metabolic on). No signs of genotoxicity and nicity were observed.  In reproductive toxicity and carcinogenicity to been performed.

# 6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable

7. Date of compilation/last revision
2 February 2016